AlphaCrest Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

AlphaCrest Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,416	Closed	-$610K	–	1402
2022 Q1	$610K	Buy	7,416 +2,011	+37%	+$206K	0.03%	801
2021 Q4	$793K	Buy	+5,405	New	+$839K	0.03%	910
2021 Q3	–	Sell	-3,800	Closed	-$614K	–	1417
2021 Q2	$614K	Sell	3,800 -1,284	-25%	-$206K	0.03%	881
2021 Q1	$871K	Buy	5,084 +3,284	+182%	+$650K	0.05%	555
2020 Q4	$395K	Buy	+1,800	New	+$389K	0.03%	793
2020 Q2	–	Sell	-3,300	Closed	-$254K	–	1174
2020 Q1	$254K	Buy	+3,300	New	+$296K	0.03%	859

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

AlphaCrest Capital Management's MRTX Position: Q2 2022 in Review

AlphaCrest Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 7,416 shares — an estimated $610K sold.

AlphaCrest Capital Management first reported a position in MRTX in Q1 2020 and held it in 6 quarters. The position peaked at $871K in Q1 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

AlphaCrest Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 7,416 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $610K.
AlphaCrest Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 6 quarters.
AlphaCrest Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $871K in Q1 2021.
230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on AlphaCrest Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.